Current trends in the use of O-(2-[18F]fluoroethyl)-L-tyrosine ([18F]FET) in neurooncology
| Autor: | Christian Filß, Felix M. Mottaghy, Heinz H. Coenen, Philipp Lohmann, Carina Stegmayr, Karl-Josef Langen, Alexander Heinzel, Gabriele Stoffels, Antje Willuweit, Johannes Ermert, Norbert Galldiks |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
Brain tumor o-(2-[f-18]fluoroethyl)-l-tyrosine (fet) Cerebral glioma 030218 nuclear medicine & medical imaging 03 medical and health sciences POSITRON-EMISSION-TOMOGRAPHY 0302 clinical medicine AMINO-ACID PET ddc:570 18F-fluoroethyl-L-tyrosine Tumor Grading Medicine Radiology Nuclear Medicine and imaging Fluoroethyl FET PET O-(2-F-18-FLUOROETHYL)-L-TYROSINE PET medicine.diagnostic_test business.industry Brain metastasis LOW-GRADE GLIOMA Neurooncology Magnetic resonance imaging RECURRENT BRAIN METASTASIS medicine.disease PROGNOSTIC VALUE Brain tumor diagnosis radiolabelled amino acids PET DYNAMIC F-18-FET PET Positron emission tomography 030220 oncology & carcinogenesis UPTAKE KINETICS Molecular Medicine business Nuclear medicine RESPONSE ASSESSMENT |
| Zdroj: | Nuclear medicine and biology 92, 78-84 (2021). doi:10.1016/j.nucmedbio.2020.02.006 |
| ISSN: | 0969-8051 |
| Popis: | The diagnostic potential of PET using the amino acid analogue O-(2-[F-18]fluoroethyl)-L-tyrosine ([F-18]FET) in brain tumor diagnostics has been proven in many studies during the last two decades and is still the subject of multiple studies every year. In addition to standard magnetic resonance imaging (MRI), positron emission tomography (PET) using [F-18]FET provides important diagnostic data concerning brain tumor delineation, therapy planning, treatment monitoring, and improved differentiation between treatment-related changes and tumor recurrence. The pharmacokinetics, uptake mechanisms and metabolism have been well described in various preclinical studies. The accumulation of [F-18]FET in most benign lesions and healthy brain tissue has been shown to be low, thus providing a high contrast between tumor tissue and benign tissue alterations. Based on logistic advantages of F-18 labelling and convincing clinical results, [F-18]FET has widely replaced short lived amino acid tracers such as L-[C-11]methyl-methionine ([C-11]MET) in many centers across Western Europe. This review summarizes the basic knowledge on [F-18]FET and its contribution to the care of patients with brain tumors. In particular, recent studies about specificity, possible pitfalls, and the utility of [F-18]FET PET in tumor grading and prognostication regarding the revised WHO classification of brain tumors are addressed. (C) 2020 Elsevier Inc. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect